Freed from the burden of paper reviews, the US Food and Drug Administration is plotting an escape from legacy free text that burdens electronic reviews with drug quality narratives.
As innovation accelerates, the time required to write and read these chemistry, manufacturing and controls narratives has become a luxury manufacturers and regulatory authorities can ill afford